With the Waxman-Markey climate change bill before the U.S. Senate, coal and energy utility lobbyists are out in force. While the legislation will only have direct effect in the United States, it will indirectly have a major influence on the negotiation of a replacement agreement to the Kyoto Protocol.
The healthcare industry is waging a "record-breaking influence campaign," spending "more than $1.4 million a day on lobbying," reports the Washington Post. "The Pharmaceutical Research and Manufacturers of America (PhRMA) doubled its spending to nearly $7 million in the first quarter of 2009, followed by Pfizer, with more than $6 million" spent in just three months.
The same day that the Waxman-Markey Climate Bill passed the U.S. House of Representatives, the oil industry examined the loopholes. The bill, which has yet to pass the Senate, would make refiners "buy allowances for carbon dioxide spewed from their plants and from vehicles when motorists burn their fuel. Imports would need permits only for the latter." So, oil companies "will probably cope ...
As the Waxman-Markey Climate Bill nears a vote in the U.S. House of Representatives, environmental groups are "teetering at the edge of existential crisis," writes Josh Harkinson. "Almost all environmental groups agree that Waxman-Markey is far from ideal," but some are supporting it, while others "believe the bill is so deeply flawed it might actually make matters worse." Critics say the bill "lines the pockets of polluters with little to show for it.
Senator Mike Enzi, ranking member of the Senate Committee on Health, Education, Labor, and Pensions (HELP), confirmed May 21 that cigarette maker